RCKT – Rocket Pharmaceuticals, Inc.

Float Short %

11.07

Margin Of Safety %

Put/Call OI Ratio

0.34

EPS Next Q Diff

0.01

EPS Last/This Y

0.71

EPS This/Next Y

0.73

Price

3.41

Target Price

7.95

Analyst Recom

2.33

Performance Q

4.92

Relative Volume

0.99

Beta

0.47

Ticker: RCKT

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-11-17	RCKT	3.05	0.20	0.50	24375
2025-11-18	RCKT	2.94	0.20	6.25	24416
2025-11-19	RCKT	2.88	0.26	0.04	25682
2025-11-20	RCKT	2.84	0.26	0.09	25680
2025-11-21	RCKT	2.92	0.26	0.00	25767
2025-11-24	RCKT	3.04	0.36	0.02	19121
2025-11-25	RCKT	3.11	0.36	0.00	19181
2025-11-26	RCKT	3.3	0.36	0.07	19248
2025-12-01	RCKT	3.16	0.35	0.53	19384
2025-12-02	RCKT	3.09	0.35	0.17	19444
2025-12-03	RCKT	3.33	0.35	0.46	19479
2025-12-04	RCKT	3.42	0.35	1.08	19485
2025-12-05	RCKT	3.32	0.35	3.67	19409
2025-12-08	RCKT	3.5	0.35	1.03	19420
2025-12-09	RCKT	3.35	0.35	0.01	19471
2025-12-10	RCKT	3.64	0.35	0.02	19610
2025-12-11	RCKT	3.44	0.35	0.04	19625
2025-12-12	RCKT	3.39	0.34	0.78	19770
2025-12-15	RCKT	3.42	0.34	0.01	19790
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-11-17	RCKT	3.05	30.4	65.7	-2.02
2025-11-18	RCKT	2.93	30.4	80.0	-2.02
2025-11-19	RCKT	2.88	30.4	72.4	-2.02
2025-11-20	RCKT	2.84	30.4	71.8	-2.02
2025-11-21	RCKT	2.92	29.8	49.2	-2.02
2025-11-24	RCKT	3.04	29.8	45.9	-2.02
2025-11-25	RCKT	3.10	29.8	56.1	-2.02
2025-11-26	RCKT	3.30	29.8	36.7	-2.02
2025-12-01	RCKT	3.15	29.8	93.4	-2.02
2025-12-02	RCKT	3.09	29.8	73.9	-2.02
2025-12-03	RCKT	3.34	29.8	31.3	-2.02
2025-12-04	RCKT	3.42	29.8	54.9	-2.02
2025-12-05	RCKT	3.32	29.8	74.7	-2.02
2025-12-08	RCKT	3.50	29.8	-	-2.02
2025-12-09	RCKT	3.36	29.8	79.0	-2.02
2025-12-10	RCKT	3.63	29.8	33.0	-2.02
2025-12-11	RCKT	3.44	29.8	83.8	-2.02
2025-12-12	RCKT	3.39	29.8	69.9	-2.02
2025-12-15	RCKT	3.41	29.8	62.3	-2.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-11-17	RCKT	-0.74	11.34	11.08
2025-11-18	RCKT	-0.79	11.34	11.08
2025-11-19	RCKT	-0.79	11.34	11.08
2025-11-20	RCKT	-0.83	11.34	11.08
2025-11-21	RCKT	-0.83	11.34	11.08
2025-11-24	RCKT	-0.77	1.75	11.08
2025-11-25	RCKT	-0.77	1.75	11.08
2025-11-26	RCKT	-0.77	1.75	11.60
2025-12-01	RCKT	-0.77	1.38	11.60
2025-12-02	RCKT	-0.77	1.38	11.60
2025-12-03	RCKT	-0.77	1.38	11.60
2025-12-04	RCKT	-0.77	1.38	11.60
2025-12-05	RCKT	-0.77	1.38	11.60
2025-12-08	RCKT	-0.77	1.36	11.60
2025-12-09	RCKT	-0.77	1.36	11.60
2025-12-10	RCKT	-0.77	1.36	11.07
2025-12-11	RCKT	-0.77	1.36	11.07
2025-12-12	RCKT	-0.77	1.36	11.07
2025-12-15	RCKT	-0.77	1.36	11.07
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

[stock_market_widget type="chart" template="candlestick" assets="RCKT" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.45

Avg. EPS Est. Current Quarter

-0.44

Avg. EPS Est. Next Quarter

-0.44

Insider Transactions

-0.77

Institutional Transactions

1.36

Beta

0.47

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-96.5

Target Price

7.95

P/E

Forward P/E

PEG

P/S

P/B

1.18

P/Free Cash Flow

EPS

-2.25

Average EPS Est. Cur. Y

-2.02

EPS Next Y. (Est.)

-1.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.99

Return on Equity vs Sector %

-103.8

Return on Equity vs Industry %

-88.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

62.3

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”RCKT” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”RCKT” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]

Rocket Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 299

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; REGENXBIO, Inc.; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

stock quote shares RCKT – Rocket Pharmaceuticals, Inc. Stock Price stock today

news today RCKT – Rocket Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RCKT – Rocket Pharmaceuticals, Inc. yahoo finance google finance

stock history RCKT – Rocket Pharmaceuticals, Inc. invest stock market

stock prices RCKT premarket after hours

ticker RCKT fair value insiders trading

RCKT – Rocket Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RCKT

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y